Larvol Delta - Pembrolizumab-and-HER2BiArmed-Activated-T-Cells-in-Treating-Patients-With-Metastatic-Castration-Resistant-Prostate-Cancer

HER2Bi-armed ATC - TransTarget

Keytruda (pembrolizumab) - Merck (MSD)

http://clinicaltrials.gov/ct2/show/NCT03406858

Mar 1, 2021

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next